BlackRock, Inc. 13D and 13G filings for Enanta Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-04-17 09:35 am Sale | 2025-03-31 | 13G | Enanta Pharmaceuticals, Inc. ENTA | BlackRock Inc. BLK | 1,673,483 7.800% | -261,228 (-13.50%) | Filing |
| 2024-01-24 5:23 pm Sale | 2023-12-31 | 13G | Enanta Pharmaceuticals, Inc. ENTA | BlackRock Inc. BLK | 1,934,711 9.200% | -43,300 (-2.19%) | Filing |
| 2023-10-06 2:34 pm Sale | 2023-09-30 | 13G | Enanta Pharmaceuticals, Inc. ENTA | BlackRock Inc. BLK | 1,978,011 9.400% | -1,775,064 (-47.30%) | Filing |
| 2023-01-31 3:17 pm Purchase | 2022-12-31 | 13G | Enanta Pharmaceuticals, Inc. ENTA | BlackRock Inc. BLK | 3,753,075 18.000% | 281,660 (+8.11%) | Filing |
| 2022-01-28 1:54 pm Purchase | 2021-12-31 | 13G | Enanta Pharmaceuticals, Inc. ENTA | BlackRock Inc. BLK | 3,471,415 17.100% | 65,415 (+1.92%) | Filing |
| 2021-01-25 4:49 pm Purchase | 2020-12-31 | 13G | Enanta Pharmaceuticals, Inc. ENTA | BlackRock Inc. BLK | 3,406,000 17.000% | 582,432 (+20.63%) | Filing |